Your right George, everyone is getting a bit too distracted by the grandiose ideas of a Sarepta takeover (May very well
be real) however approval for phase 2b trials will mean they have reviewed the safety data and decided we have the right to progress! This is huge! Like you said as of that crucial moment it’s not just DMD but a whole slew of indications we can then enter phase 2 trials for. Safety is the the one big hurdle for a new drug and if we pass that then we are derisked in a major major way. A 500 million plus market cap is justified by this alone even without Sarepta onboard.
Your right George, everyone is getting a bit too distracted by...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |